Home > Insider Trading > Filing (0001209191-23-003383)

Filing Details

Accession Number:: 0001209191-23-003383
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-01-13 21:00:18
Reporting Period:: 2023-01-11

Accepted Time:: 2023-01-13 21:00:18
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1630627	Treace Medical Concepts Inc.	TMCI	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1183554	Barry F Bays	C/O Treace Medical Concepts, Inc. 100 Palmetto Park Place Ponte Vedra FL 32081		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2023-01-11	9,719	$24.32	1,436,793	No	4	S	Direct
Common Stock	Disposition	2023-01-12	23,695	$25.13	1,413,098	No	4	S	Direct
Common Stock	Disposition	2023-01-12	21,841	$25.94	1,391,257	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.0500 to $24.755 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Due to an inadvertent error, the value in Table 1, Box 5 of the Form 4 filed on September 29, 2022 was incorrectly reported. This value corrects the aforementioned error.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.5500 to $25.5400 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.5500 to $25.9900 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.